Long-Term Follow-Up of Patients at High Risk for Nephropathy After Contrast Exposure

Abacı, Okay; Harmankaya, Özlem; Koçaş, Betül Balaban; Kocas, Cuneyt; Bostan, Cem; Coşkun, Uğur; Yıldız, Ahmet; Ersanlı, Murat

doi:10.1177/0003319714546527

Cited by 35 publications

(34 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CI-AKI is now the third most frequent cause of hospital-acquired kidney dysfunction [3]. CI-AKI has been shown to be associated with an increased risk of mortality, increased costs of medical care, and prolonged hospitalization [4, 5]. …”

Section: Introductionmentioning

confidence: 99%

Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro

Xie

Cao

Yang

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Background. Contrast-induced acute kidney injury (CI-AKI) is one of the main causes of iatrogenic acute kidney injury (AKI); however, therapeutic strategies for AKI remain limited. This study aims to explore the effect of relaxin (RLX) on contrast-induced HK-2 apoptosis and its underlying mechanisms. Methods. Renal tubular epithelial cells (HK-2) were incubated either with or without ioversol, human H2 relaxin, and LY294002 (the inhibitor of the PI3K/Akt signal pathway). Cell viability was evaluated with a CCK-8 assay. Apoptotic morphologic alterations were observed using the Hoechst 33342 staining method. Apoptosis was detected with Annexin V staining. Western blot analysis was employed to measure the expression of pAkt (S473), Akt, cleaved caspase-3, Bcl-2, Bax, and actin proteins. Results. Ioversol reduced the viability of HK-2 cells. Western blotting results revealed decreased expression of phosphorylated Akt in cells treated with ioversol. The activities of caspase-3 and Bax protein increased, while the expression of Bcl-2 protein decreased. As a result, the Bax/Bcl-2 ratio increased after treatment with ioversol. These effects were reversed when HK-2 cells were cotreated with RLX. However, with preadministration of PI3K/Akt pathway inhibitor LY294002, the effect of RLX was blocked. Conclusion. Our study demonstrates that relaxin attenuates ioversol induced cell apoptosis via activation of the PI3K/Akt signaling pathway, suggesting that RLX might play a protective role in the treatment of CI-AKI.

show abstract

Section: Introductionmentioning

confidence: 99%

Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro

Xie

Cao

Yang

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…A recent study by Abacı et al [16] reported that contrast media exposure in patients whose creatinine clearance is less than 60 ml/min increases their long-term mortality. Furthermore, the longer procedure times in this particular group (door-to-balloon, etc.)…”

Section: Discussionmentioning

confidence: 99%

The value of the Clinical SYNTAX Score in predicting long-term prognosis in patients with ST-segment elevation myocardial infarction who have undergone primary percutaneous coronary intervention

Çetinkal

Dogan²,

Kocas³

et al. 2016

Coronary Artery Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our study has shown that CIN, which is one of the important causes of mortality, is still common among hospitalised patients. In addition, contrast medium exposure may lead to long-term outcomes such as death and dialysis-requiring renal failure [13].…”

Section: Discussionmentioning

confidence: 99%

CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention

Çiçek¹,

Yıldırım²

2018

Kardiol Pol

View full text Add to dashboard Cite

A b s t r a c t Background and aim:We aimed to investigate the predictive value of the CHA 2 DS 2 -VASc score in the development of contrast-induced nephropathy (CIN). Methods:A total of 2972 patients who had been diagnosed with ST elevation myocardial infarction (STEMI) and who had undergone primary coronary angioplasty were included in the study. The patients were divided into three groups according to the CHA 2 DS 2 -VASc score, i.e.: low risk (1 point), intermediate risk (2 points), and high risk (≥ 3 points). The groups were followed with regard to CIN development. Results:The median CHA 2 DS 2 -VASc score was significantly higher in the CIN(+) group compared to the CIN(-) group (3 vs. 2, p < 0.001). The rate of CIN was 3.32-fold higher (OR 3.32, 95% CI 1.98-5.55, p < 0.001) in the high-risk group (CHA 2 DS 2 -VASc ≥ 3) compared to the low-risk group (CHA 2 DS 2 -VASc = 1). Age (OR 1.25, 95% CI 1.14-1.36, p < 0.001), female gender (OR 1.52, 95% CI 1.23-1.89, p < 0.001), hypertension (OR 1.50, 95% CI 1.265-1.78, p < 0.001), peak creatinine kinase-MB (OR 1.15, 95% CI 1.10-1.21, p < 0.001), and the Killip score > 1 (OR 4.25, 95% CI 3.10-5.82, p < 0.001) were found to be independent predictors for CIN development. Conclusions:The CHA 2 DS 2 -VASc score is an independent and strong predictor of CIN development in patients with acute STEMI.

show abstract

Long-Term Follow-Up of Patients at High Risk for Nephropathy After Contrast Exposure

Cited by 35 publications

References 20 publications

Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro

Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro

The value of the Clinical SYNTAX Score in predicting long-term prognosis in patients with ST-segment elevation myocardial infarction who have undergone primary percutaneous coronary intervention

CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention

Contact Info

Product

Resources

About